

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled trial

Lancet Respiratory Medicine, the
8, 963-974

DOI: [10.1016/S2213-2600\(20\)30318-0](https://doi.org/10.1016/S2213-2600(20)30318-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 497-504.	4.3	15
2	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 455-466.	2.4	7
3	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
4	Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 3388.	2.4	24
5	Treatment of myocardial fibrosis in systemic sclerosis with tocilizumab. <i>Rheumatology</i> , 2021, 60, e205-e206.	1.9	4
6	Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. <i>Cell Reports Medicine</i> , 2020, 1, 100140.	6.5	42
7	Données récentes sur la prise en charge clinique de la sclérodémie systémique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 24-31.	0.0	0
8	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 641-650.	0.9	25
9	Parry Romberg disease with En Coup de Sabre Scleroderma: Effect of tocilizumab on periodontal bone inflammation. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 206-210.	1.7	4
10	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110351.	2.7	8
11	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2021, 7, 00235-2020.	2.6	11
12	New insights into the treatment of CTD-ILD. <i>Nature Reviews Rheumatology</i> , 2021, 17, 79-80.	8.0	14
13	Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. <i>Advanced Biology</i> , 2021, 5, e2000168.	2.5	8
14	IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGF β -mediated activation of dermal fibroblasts. <i>Rheumatology</i> , 2021, 60, 5820-5826.	1.9	36
15	The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease. <i>Immunotherapy</i> , 2021, 13, 241-256.	2.0	16
16	The Treatment of Lung Involvement in Systemic Sclerosis. <i>Pharmaceuticals</i> , 2021, 14, 154.	3.8	13
17	The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting. <i>Current Molecular Medicine</i> , 2022, 22, 209-239.	1.3	14
18	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. <i>ACR Open Rheumatology</i> , 2021, 3, 295-304.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	7.1	18
20	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. <i>Pharmaceuticals</i> , 2021, 14, 251.	3.8	2
21	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. <i>Journal of Clinical Medicine</i> , 2021, 10, 1330.	2.4	11
22	Systemic sclerosis (scleroderma): remaining challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 438-438.	1.7	6
23	The Diagnosis and Treatment of Pulmonary Fibrosis. <i>Deutsches A&#x0308;rzteblatt International</i> , 2021, 118, .	0.9	10
24	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 240-248.	4.3	27
25	Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. <i>Rheumatology</i> , 2021, 60, 3945-3946.	1.9	9
26	C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. <i>Modern Rheumatology</i> , 2022, 32, 141-148.	1.8	3
28	Contemporary Concise Review 2020: Interstitial lung disease. <i>Respirology</i> , 2021, 26, 604-611.	2.3	0
30	Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy. <i>Cells</i> , 2021, 10, 1104.	4.1	9
31	A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. <i>Contemporary Clinical Trials</i> , 2021, 104, 106333.	1.8	3
32	Does tocilizumab have a role in dermatology? A review of clinical applications, its adverse side effects and practical considerations. <i>Dermatologic Therapy</i> , 2021, 34, e14990.	1.7	6
33	The target on B cells in Systemic Sclerosis: a "æmidsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	2.2	5
34	Tocilizumab Prevents Progression of Early Systemic Sclerosis"Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1301-1310.	5.6	104
35	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	4.1	28
36	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. <i>RMD Open</i> , 2021, 7, e001524.	3.8	3
37	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. <i>Lancet Rheumatology, The</i> , 2021, 3, e321-e323.	3.9	1
38	Update in Interstitial Lung Disease 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1343-1352.	5.6	21

#	ARTICLE	IF	CITATIONS
39	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	3.5	30
40	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine</i> , 2021, 9, 560-562.	10.7	6
41	The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 388-395.	2.6	15
42	Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 684699.	4.8	39
43	New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy. <i>Life</i> , 2021, 11, 610.	2.4	14
44	Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease. <i>Archives of Rheumatology</i> , 2021, 36, 548-559.	0.9	0
45	Management of Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 295-310.	2.1	8
47	Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105221.	1.6	0
48	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , 2021, 3, e489-e497.	3.9	105
49	Systemic Sclerosis-associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , 2022, 74, 13-27.	5.6	71
50	Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 703780.	4.8	3
51	Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1584-1593.	0.9	21
52	The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 227-235.	1.7	2
53	Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience. <i>Journal of Rheumatology</i> , 2022, 49, 68-73.	2.0	6
54	Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. <i>Current Opinion in Rheumatology</i> , 2021, 33, 480-485.	4.3	11
55	Promise and challenge of systemic sclerosis therapies. <i>Nature Reviews Rheumatology</i> , 2021, 17, 581-582.	8.0	2
56	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 311-333.	2.4	1
57	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 757-780.	1.9	5

#	ARTICLE	IF	CITATIONS
60	Review for best practice in clinical rheumatology juvenile systemic sclerosis – Updates and practice points. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101688.	3.3	6
62	Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. Current Opinion in Rheumatology, 2021, 33, 463-470.	4.3	35
63	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	6.5	20
65	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	13.7	47
66	An update on recent randomized clinical trials in systemic sclerosis. Joint Bone Spine, 2021, 88, 105184.	1.6	2
67	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	1.8	45
68	An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine, 2021, 146, 155645.	3.2	11
69	Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine, 2021, 148, 155684.	3.2	13
70	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study. Journal of Scleroderma and Related Disorders, 2021, 6, 154-164.	1.7	8
71	Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Frontiers in Medicine, 2021, 8, 743977.	2.6	11
72	Revue des récents essais randomisés dans la sclérodémie systémique. Revue Du Rhumatisme (Edition) Tj FTQq 0 0 rgBT /Ove	0.0	0
73	Dysregulation of Type I Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?. Current Treatment Options in Rheumatology, 2021, 7, 349-360.	1.4	9
74	Esophageal Dysfunction in Systemic Sclerosis: An Update. Rheumatology and Therapy, 2021, 8, 1535-1549.	2.3	10
75	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics, 2021, 11, 2007.	2.6	6
76	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmunity Reviews, 2021, 20, 102978.	5.8	17
77	Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells. International Journal of Molecular Sciences, 2021, 22, 11793.	4.1	14
78	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmunity Reviews, 2021, 20, 102981.	5.8	9
79	Treatment of systemic sclerosis. Presse Medicale, 2021, 50, 104088.	1.9	10

#	ARTICLE	IF	CITATIONS
81	Symptom experience of limited cutaneous systemic sclerosis from the Patientsâ€™ perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151926.	3.4	12
82	Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2022, 191, 106689.	2.9	7
83	Purinergic signaling in systemic sclerosis. <i>Rheumatology</i> , 2021, , .	1.9	0
84	Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 283.	3.5	4
85	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 163-174.	1.9	3
86	Serotonin and Systemic sclerosis. An emerging player in pathogenesis. <i>Joint Bone Spine</i> , 2021, 89, 105309.	1.6	3
87	Interstitial lung disease in a woman with rheumatoid arthritis treated with denosumab: A case report. <i>Modern Rheumatology Case Reports</i> , 2022, 6, 155-159.	0.7	3
89	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosisâ€“Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	5.6	57
90	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. <i>Diagnostics</i> , 2021, 11, 2274.	2.6	2
91	Choosing pharmacotherapy for ILD in patients with connective tissue disease. <i>Breathe</i> , 2021, 17, 210114.	1.3	1
92	The Effect of Anti-CCP Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. <i>ACR Open Rheumatology</i> , 2022, 4, 345-351.	2.1	12
93	Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis. <i>Rheumatology</i> , 2022, , .	1.9	3
95	Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. <i>Biomedicines</i> , 2022, 10, 318.	3.2	14
96	Challenges for Clinical Drug Development in Pulmonary Fibrosis. <i>Frontiers in Pharmacology</i> , 2022, 13, 823085.	3.5	20
97	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. <i>Rheumatology</i> , 2022, 61, 3132-3148.	1.9	4
98	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 163.	3.2	16
99	Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. <i>Biomedicines</i> , 2022, 10, 316.	3.2	8
100	Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 321-342.	6.5	6

#	ARTICLE	IF	CITATIONS
102	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization – WSF Skin Ultrasound Group. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151954.	3.4	14
103	Systemic sclerosis in adults. Part II: management and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 957-978.	1.2	7
104	Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies. <i>Rheumatology</i> , 2022, 61, 3677-3685.	1.9	5
105	Interstitial pneumonia with autoimmune features. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 1-20.	0.1	0
106	Targeted Immunotherapy for Autoimmune Disease. <i>Immune Network</i> , 2022, 22, e9.	3.6	46
108	Lung involvement in systemic sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 73-103.	0.1	0
109	Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. <i>Biomedicines</i> , 2022, 10, 504.	3.2	2
110	Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 854-860.	0.9	13
111	Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. <i>Biomedicines</i> , 2022, 10, 434.	3.2	5
112	Future Treatment Options in Systemic Sclerosis – Potential Targets and Ongoing Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 1310.	2.4	9
113	Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?. <i>Frontiers in Medicine</i> , 2022, 9, 855740.	2.6	3
115	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. <i>Rheumatology</i> , 2022, 61, 4491-4496.	1.9	9
116	IL-33/regulatory T cell axis suppresses skin fibrosis. <i>Journal of Investigative Dermatology</i> , 2022, , .	0.7	4
117	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. <i>Rheumatology</i> , 2022, 61, 4035-4046.	1.9	6
118	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. <i>Nature Reviews Rheumatology</i> , 2022, 18, 276-285.	8.0	18
119	Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease. <i>Cells</i> , 2022, 11, 843.	4.1	1
120	Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis. <i>Biomedicines</i> , 2022, 10, 607.	3.2	9
121	Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1521-1541.	3.5	21

#	ARTICLE	IF	CITATIONS
122	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. <i>Journal of Investigative Dermatology</i> , 2022, 142, 811-822.	0.7	5
123	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 472-489.	6.5	13
124	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.7	3
125	Focused on the Target in Systemic Sclerosis—Interstitial Lung Disease: Another Arrow in the Quiver?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 608-610.	5.6	2
126	Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma. <i>Clinical Rheumatology</i> , 2022, 41, 2179-2187.	2.2	3
127	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
128	Advances with pharmacotherapy for the treatment of interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 483-495.	1.8	0
129	Early Radiographic Progression of Scleroderma. <i>Chest</i> , 2022, 161, 1310-1319.	0.8	9
131	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. <i>Rheumatology</i> , 2022, 61, 3401-3407.	1.9	3
132	Current advances in the treatment of systemic sclerosis. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102211.	3.5	23
134	Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2022, 24, 166-173.	4.7	8
135	Single-cell analysis identifies the interaction of altered renal tubules with basophils orchestrating kidney fibrosis. <i>Nature Immunology</i> , 2022, 23, 947-959.	14.5	37
136	Management of Connective Tissue Disease—related Interstitial Lung Disease. <i>Current Pulmonology Reports</i> , 2022, 11, 86-98.	1.3	11
137	Calcineurin inhibitors in systemic sclerosis — a systematic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210923.	2.7	1
138	The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
139	Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2023, 62, S143-S153.	1.9	6
140	Autologous Skin Fibroblast—Based PLGA Nanoparticles for Treating Multiorgan Fibrosis. <i>Advanced Science</i> , 2022, 9, .	11.2	8
141	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. <i>Current Rheumatology Reports</i> , 0, , .	4.7	3

#	ARTICLE	IF	CITATIONS
142	Use of Biologics for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. <i>Modern Rheumatology</i> , 0, , .	1.8	1
143	Treatment approach to connective tissue disease-associated interstitial lung disease. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102245.	3.5	6
144	Cytokine-producing B cell balance associates with skin fibrosis in patients with systemic sclerosis. <i>Journal of Dermatology</i> , 0, , .	1.2	3
145	Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. <i>Rheumatology</i> , 2023, 62, SI32-SI42.	1.9	4
146	Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients. <i>Internal Medicine Journal</i> , 2023, 53, 1147-1153.	0.8	3
148	Pathogenetic Aspects of Systemic Sclerosis: A View Through the Prism of B Cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	59
149	JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	16
150	Pregnancy Considerations for Patients With Interstitial Lung Disease. <i>Chest</i> , 2022, 162, 1093-1105.	0.8	2
151	Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. <i>BMJ</i> , The, 0, , e066354.	6.0	14
152	The Role of B Cells in Scleroderma Lung Disease Pathogenesis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	6
153	Current status and prospects of IL-6-targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	3.1	10
154	Role of B-Cell in the Pathogenesis of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	20
155	IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
156	Assessment of disease outcome measures in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 527-541.	8.0	10
157	Macrophages as determinants and regulators of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2023, 62, 535-545.	1.9	11
158	Recent advances in the management of systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 441-447.	2.6	6
159	Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2022, 74, 2003-2014.	5.6	12
160	Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. <i>Histochemistry and Cell Biology</i> , 2022, 158, 415-434.	1.7	8

#	ARTICLE	IF	CITATIONS
161	Toll-like receptor triggering in systemic sclerosis: time to target. <i>Rheumatology</i> , 2023, 62, SI12-SI19.	1.9	5
162	Systemic sclerosis in the time of COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e566-e575.	3.9	14
163	Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211164.	2.7	7
164	Management of progressive pulmonary fibrosis associated with connective tissue disease. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 765-774.	2.5	6
165	Reduced Cathepsin L expression and secretion into the extracellular milieu contribute to lung fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2023, 62, 1306-1316.	1.9	6
166	Recommendations for the execution and reporting of skin ultrasound in systemic sclerosis: an international collaboration under the WSF skin ultrasound group. <i>RMD Open</i> , 2022, 8, e002371.	3.8	6
168	Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosisâ€“associated interstitial lung disease. <i>Rheumatology</i> , 0, , .	1.9	1
169	Interstitial lung diseases. <i>Lancet</i> , The, 2022, 400, 769-786.	13.7	99
170	New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. <i>Journal of Clinical Medicine</i> , 2022, 11, 4631.	2.4	18
171	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787.	0.9	11
173	Cellular and molecular diversity in rheumatic autoimmune diseases. <i>Seminars in Immunology</i> , 2022, , 101648.	5.6	0
174	Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S13-S26.	3.6	5
175	Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin. <i>Arthritis Care and Research</i> , 2023, 75, 1469-1480.	3.4	6
176	Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e668-e678.	3.9	8
177	Immunomodulatory treatment of interstitial lung disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211170.	2.6	15
178	A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. <i>Rheumatology</i> , 2023, 62, 1543-1551.	1.9	5
179	Scleroderma autoantibodies in guiding monitoring and treatment decisions. <i>Current Opinion in Rheumatology</i> , 2022, 34, 302-310.	4.3	7
181	Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. <i>Rheumatology</i> , 2023, 62, 1877-1886.	1.9	2

#	ARTICLE	IF	CITATIONS
182	A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. <i>RMD Open</i> , 2022, 8, e002359.	3.8	9
183	Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	9
184	Systemic Sclerosis Association with Malignancy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 398-416.	6.5	7
185	Severe Infections in Patients Treated with Tocilizumab for Systemic Diseases Other Than Rheumatoid Arthritis: A Retrospective Multicenter Observational Study. , 2023, 10, 18-22.		0
186	VII. Clinical Approach for Interstitial Lung Disease in Connective Tissue Diseases-including Molecular Targeted Therapy-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2206-2212.	0.0	0
187	Skin disorders and interstitial lung disease: Part I—Screening, diagnosis, and therapeutic principles. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 751-764.	1.2	1
188	Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research. <i>Chest</i> , 2023, 163, 586-598.	0.8	5
189	Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 767-782.	1.2	2
190	Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. <i>RMD Open</i> , 2022, 8, e002477.	3.8	7
191	Normal percentile reference curves for skin ultrasound thickness and stiffness at Rodnan sites. <i>RMD Open</i> , 2022, 8, e002577.	3.8	4
193	Patient and physician global assessments of disease status in systemic sclerosis. <i>Arthritis Care and Research</i> , 0, , .	3.4	1
194	Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 683-693.	8.0	18
195	The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	1.0	6
197	Advances in the Treatment of Systemic Sclerosis. , 2022, 1, 61.		0
198	Systemic sclerosis. <i>Lancet, The</i> , 2023, 401, 304-318.	13.7	73
199	Case report: A successful second autologous hematopoietic stem cell transplantation in refractory systemic sclerosis, with positive effect on skin involvement, pulmonary function and microcirculation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
200	Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	1
201	Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 517-534.	1.0	5

#	ARTICLE	IF	CITATIONS
203	Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis. <i>Science Immunology</i> , 2022, 7, .	11.9	8
205	COVID-19 and protection of vaccination in patients with systemic sclerosis-associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832211432.	1.7	2
206	Dysregulated B cell function and disease pathogenesis in systemic sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
207	Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. <i>Respiratory Research</i> , 2023, 24, .	3.6	40
208	Diagnosing lung involvement in inflammatory rheumatic diseases—Where do we currently stand?. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
209	COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection. <i>Journal of Translational Autoimmunity</i> , 2023, 6, 100190.	4.0	0
210	Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
211	Systemic sclerosis. Part I: epidemiology, diagnosis and therapy. <i>BJA Education</i> , 2023, 23, 66-75.	1.4	1
212	Blocage de l'IL-6 hors autorisation de mise sur le marché. , 2022, , 215-224.		0
213	Skin ultrasound in systemic sclerosis: Where do we stand and where shall we go?. <i>International Journal of Rheumatic Diseases</i> , 2023, 26, 193-194.	1.9	0
214	Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8. <i>JACC Basic To Translational Science</i> , 2023, 8, 479-496.	4.1	3
215	Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2405.	4.1	5
216	3. Recent Progress in Management of Interstitial Lung Disease Associated with Connective Tissue Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 90a-96a.	0.0	0
217	Role of rituximab in the treatment of systemic sclerosis: A literature review. <i>Modern Rheumatology</i> , 2023, 33, 1068-1077.	1.8	3
218	Scleroderma Skin. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 249-262.	1.9	0
219	Treatment of Inflammatory Arthritis in Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 337-343.	1.9	1
220	Interstitial Lung Disease. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 279-293.	1.9	3
221	Connective Tissue Disease Associated Interstitial Lung Disease. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 229-244.	1.9	1

#	ARTICLE	IF	CITATIONS
222	The Exciting Future for Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 445-462.	1.9	1
223	Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Immunology and Allergy Clinics of North America</i> , 2023, 43, 411-433.	1.9	0
224	The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2963.	4.1	8
225	Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
226	First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3645.	4.1	2
228	Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements. <i>Expert Review of Respiratory Medicine</i> , 2023, 17, 71-80.	2.5	0
230	Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. <i>RMD Open</i> , 2023, 9, e002859.	3.8	7
231	Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. <i>Life</i> , 2023, 13, 599.	2.4	2
232	Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. <i>RMD Open</i> , 2023, 9, e002850.	3.8	9
233	State-of-the-art evidence in the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2023, 19, 212-226.	8.0	21
234	Immunopathogenesis and treatment of scleroderma. , 2023, , 427-435.		0
235	Clinical Trial Enrichment in Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Chest</i> , 2023, 163, 475-476.	0.8	0
236	ERS International Congress 2022: highlights from the Thoracic Surgery and Lung Transplantation Assembly. <i>ERJ Open Research</i> , 2023, 9, 00671-2022.	2.6	0
237	Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	3
238	Recent advances in the treatment of systemic sclerosis associated interstitial lung disease. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
239	Advances in biological and targeted therapies for systemic sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 325-339.	3.1	4
240	Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities. <i>Arthritis and Rheumatology</i> , 0, , .	5.6	0
241	Pharmacological management of systemic sclerosis associated interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-10.	1.8	0

#	ARTICLE	IF	CITATIONS
242	Inflammatory Networks in Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 2212.	3.7	1
243	Systemic Sclerosis and the Lung. , 2023, , 193-205.		0
244	Development and validation of algorithms to build an electronic health record based cohort of patients with systemic sclerosis. <i>PLoS ONE</i> , 2023, 18, e0283775.	2.5	1
245	Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis. <i>Rheumatology</i> , 2024, 63, 103-110.	1.9	4
246	Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2023, 75, 1608-1618.	5.6	4
247	New therapeutic approaches against pulmonary fibrosis. <i>Bioorganic Chemistry</i> , 2023, 138, 106592.	4.1	2
248	Systemic sclerosis associated interstitial lung disease: a survey of current practices in France. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2023, 15, 1759720X2311597.	2.7	1
249	Interstitial Pneumonia with Autoimmune Features: 8 Years after Nomenclature and Classificationâ€”Where are We Not and Where Are We Headed?. <i>Current Pulmonology Reports</i> , 0, , .	1.3	0
250	Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2023, 13, .	3.3	4
251	Human dental pulp stem cells (hDPSCs) promote the lipofibroblast transition in the early stage of a fibro-inflammatory process. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	2
252	Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: A Focus on the Role of the Pharmacist. <i>Integrated Pharmacy Research & Practice</i> , 0, Volume 12, 101-112.	1.5	0
253	Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
254	Induction of pro-inflammatory genes by fibronectin DAMPs in three fibroblast cell lines: Role of TAK1 and MAP kinases. <i>PLoS ONE</i> , 2023, 18, e0286390.	2.5	0
256	Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. <i>Rheumatology</i> , 2024, 63, 639-647.	1.9	4
257	Systemic Sclerosis-Associated Interstitial Lung Disease: Prevalence and Risk Factors. <i>Journal of Clinical Rheumatology and Immunology</i> , 0, , 1-10.	0.4	0
258	Interstitial lung diseases: an overview. , 2023, , 23-39.		0
260	Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
261	Overview on the Link Between the Complement System and Auto-Immune Articular and Pulmonary Disease. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 15, 65-79.	1.6	2

#	ARTICLE	IF	CITATIONS
262	Î±vÎ²3 Integrin as a Link between the Development of Fibrosis and Thyroid Hormones in Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8927.	4.1	2
263	Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges. <i>ERJ Open Research</i> , 2023, 9, 00145-2023.	2.6	2
264	Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. <i>Rheumatology</i> , 2024, 63, 472-481.	1.9	4
265	Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. <i>European Respiratory Journal</i> , 2023, 61, 2202071.	6.7	12
266	Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis. <i>Respiratory Medicine</i> , 2023, 216, 107329.	2.9	2
267	Role of Extracellular Vesicles in the Propagation of Lung Fibrosis in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2023, 75, 2228-2239.	5.6	2
268	Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	1
269	The Role of SOX9 in IGF-II-Mediated Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11234.	4.1	0
270	Efficacy and safety of Atocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial. <i>Modern Rheumatology</i> , 2024, 34, 530-540.	1.8	0
271	Systemic therapy in juvenile localized scleroderma. <i>Expert Review of Clinical Immunology</i> , 0, , 1-14.	3.0	0
272	Weak to no correlation between quantitative high-resolution computed tomography metrics and lung function change in fibrotic diseases. <i>ERJ Open Research</i> , 2023, 9, 00210-2023.	2.6	1
273	Further insight into systemic sclerosis from the vasculopathy perspective. <i>Biomedicine and Pharmacotherapy</i> , 2023, 166, 115282.	5.6	2
274	Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival. <i>Chest</i> , 2024, 165, 132-145.	0.8	0
275	A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	1
276	A Scoping Review of the Efficacy and Safety of Methotrexate Compared to Mycophenolate Mofetil in the Treatment of Juvenile Localized Scleroderma in Children and Young Adults. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.6	0
277	Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials. <i>Current Opinion in Rheumatology</i> , 0, , .	4.3	0
278	Rituximab in the treatment of systemic sclerosis. Literature review. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 466-474.	1.0	0
279	Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12152.	4.1	0

#	ARTICLE	IF	CITATIONS
280	Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy. <i>ACR Open Rheumatology</i> , 2023, 5, 547-555.	2.1	2
281	Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease. <i>Cells</i> , 2023, 12, 2238.	4.1	1
282	Treatable Traits in Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 65, 251-276.	6.5	3
283	Back to the future: targeting the extracellular matrix to treat systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2023, 19, 713-723.	8.0	2
284	Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?. <i>Autoimmunity Reviews</i> , 2023, , 103439.	5.8	2
285	An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease. <i>Revista Colombiana De Reumatología</i> , 2024, 31, S26-S34.	0.1	0
286	Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab. , 2023, 2, 17.		1
288	The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosisâ€“Associated Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 6680.	2.4	0
289	Investigational drugs for the treatment of scleroderma: whatâ€™s new?. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 601-614.	4.1	0
290	Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 1568-1579.	0.9	2
291	Tocilizumab in systemic sclerosis treatment: a case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 4586-4588.	1.1	1
292	Budget impact analysis of tocilizumab in progressive fibrosing interstitial lung disease. <i>Minerva Respiratory Medicine</i> , 2023, 62, .	0.2	0
294	Enrichment strategies for clinical trials targeting skin fibrosis and interstitial lung disease in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2023, 35, 349-355.	4.3	0
295	Beyond very early systemic sclerosis: deciphering preâ€™scleroderma and its trajectories to open new avenues for preventive medicine. <i>Lancet Rheumatology</i> , The, 2023, 5, e683-e694.	3.9	3
296	Updates on translational and clinical research in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2023, 35, 299-300.	4.3	0
297	Tocilizumab in Patients with Systemic Sclerosisâ€“associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. <i>Annals of the American Thoracic Society</i> , 0, , .	3.2	0
298	Treatment of Systemic Sclerosisâ€“associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2024, 209, 137-152.	5.6	10
299	Serum Câ€™reactive protein is associated with earlier mortality across different interstitial lung diseases. <i>Respirology</i> , 0, , .	2.3	1

#	ARTICLE	IF	CITATIONS
300	An interleukin 6 responsive plasma cell signature is associated with disease progression in systemic sclerosis interstitial lung disease. <i>IScience</i> , 2023, 26, 108133.	4.1	1
301	Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis. <i>Thorax</i> , 2023, 78, 1188-1196.	5.6	2
302	Outcomes of systemic sclerosis associated interstitial lung disease patients with a persistent inflammatory phenotype based on serial CRP measurements. <i>Thorax</i> , 2023, 78, 1166-1167.	5.6	0
304	Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4797-4807.	3.6	0
305	Should we use nintedanib as early therapy in patients with SSc-ILD?. <i>Autoimmunity Reviews</i> , 2023, , 103463.	5.8	1
306	Current Landscape and Future Directions of Patient Education in Adults with Interstitial Lung Disease. <i>ATS Scholar</i> , 2024, 5, 184-205.	1.3	0
307	Summary for Cliniciansâ€”Clinical Practice Guideline for the Treatment of Systemic Sclerosisâ€”associated Interstitial Lung Disease: Evidence-based Recommendations. <i>Annals of the American Thoracic Society</i> , 0, , .	3.2	0
308	Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with antiâ€”topoisomerase I antibody. <i>Journal of Dermatology</i> , 2024, 51, 62-69.	1.2	0
309	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2023, 5, e660-e669.	3.9	1
310	Chromosome Segregation Defects in Scleroderma. , 0, , .		0
311	Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. <i>Clinical Immunology</i> , 2023, 254, 109695.	3.2	3
312	Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review. <i>RMD Open</i> , 2023, 9, e003426.	3.8	0
313	Delving into Molecular Pathways: Analyzing the Mechanisms of Action of Monoclonal Antibodies Integrated in IMGT/mAb-DB for Myasthenia Gravis. <i>Vaccines</i> , 2023, 11, 1756.	4.4	0
314	Peimine Alleviated Bleomycin-Induced Pulmonary Fibrosis in Mice Through Reducing Epithelial-Mesenchymal Transition, Inflammation and Oxidative Stress and Regulating Host Metabolism. <i>Natural Product Communications</i> , 2023, 18, .	0.5	0
315	Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 1960.	2.0	0
317	Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
318	Understanding interleukin 11 as a disease gene and therapeutic target. <i>Biochemical Journal</i> , 2023, 480, 1987-2008.	3.7	2
319	SLE criteria are by necessity still based on clinical (and immunological) criteria items. <i>Expert Review of Clinical Immunology</i> , 2024, 20, 305-311.	3.0	0

#	ARTICLE	IF	CITATIONS
320	Recent Advances in Treatment of Systemic Sclerosis and Morphea. American Journal of Clinical Dermatology, 2024, 25, 213-226.	6.7	0
321	Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists. Annals of Pharmacotherapy, 0, , .	1.9	0
322	Long-lasting improvement of refractory antisynthetase syndrome with tocilizumab: a report of two cases. RMD Open, 2023, 9, e003599.	3.8	1
323	A pulmonary perspective on current challenges in connective tissue diseases. European Journal of Internal Medicine, 2023, , .	2.2	0
325	Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022. Expert Review of Clinical Immunology, 0, , 1-18.	3.0	0
326	Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Frontiers of Medicine, 2023, 17, 1080-1095.	3.4	0
327	Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry. Respiratory Research, 2024, 25, .	3.6	1
329	Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort. RMD Open, 2024, 10, e003658.	3.8	0
330	Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial. Seminars in Arthritis and Rheumatism, 2024, 65, 152376.	3.4	0
332	Isoform-selective TGF- β 3 inhibition for systemic sclerosis. Med, 2024, 5, 132-147.e7.	4.4	0
333	C-reactive protein as a candidate biomarker in fibrotic interstitial lung disease. Respirology, 2024, 29, 195-198.	2.3	0
334	Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis. Molecular Aspects of Medicine, 2024, 96, 101252.	6.4	0
335	Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention. Life, 2024, 14, 229.	2.4	0
337	Th17/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH. Cytokine, 2024, 176, 156534.	3.2	0
338	Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis. International Journal of Molecular Sciences, 2024, 25, 2299.	4.1	0
339	Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development. International Journal of Molecular Sciences, 2024, 25, 2682.	4.1	0
340	Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?. Revue De Medecine Interne, 2024, , .	1.0	0
341	Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT. Efficacy and Mechanism Evaluation, 0, , 1-68.	0.7	0

#	ARTICLE	IF	CITATIONS
342	Association of serum Ly6/PLAUR domain-containing protein 1 levels with skin sclerosis in systemic sclerosis. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
343	Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 0, , .	2.4	0
344	Novel and potential future therapeutic options in systemic autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
346	Bridges of Pulmonology 2023 proceedings: Highlights in the field of interstitial lung diseases. <i>Pneumon</i> , 2024, 37, 1-4.	0.3	0
347	Clinical characteristics of patients with connective tissue disease-related interstitial lung disease: a retrospective analysis. <i>Clinical Rheumatology</i> , 2024, 43, 1693-1701.	2.2	0
348	Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. <i>Clinical Pharmacology and Therapeutics</i> , 0, , .	4.7	0